Article Text

Download PDFPDF

3PC-051 Impact of ophthalmological preparations in the pharmacy service of a reference hospital
  1. I Salar Valverde,
  2. N Manresa Ramon,
  3. M Gil Candel,
  4. M Onteniente Candela,
  5. C Pastor Mondejar,
  6. C Caballero Requejo,
  7. C Iniesta Navalon,
  8. M Garcia Coronel,
  9. E Urbieta Sanz
  1. Hospital General Universitario Reina Sofia, Hospital Pharmacy, Murcia, Spain


Background There are many medicinal products that, although they have shown efficacy and safety in different ophthalmological indications, are not authorised or commercially available for ophthalmic administration.1

Purpose To evaluate the elaborations of ophthalmological medicines which must be prepared in the pharmacy service.

Material and methods This was a retrospective study of ophthalmological preparations in a reference hospital from January 2016 to December 2017. The parameters measured were treatment, administration (eye drops or intraocular injections) and economic impact.

Data source: SAVAC computer system.

Results Over the studied period, 37 618 ophthalmological preparations were elaborated in our laboratory: 20 430 (2017) and 17 188 (2016).

The preparation of eye drops were 16 838 (2017) and 13 990 (2016). During 2017, we observed that autologous serum 20% supposed 8810 preparations, cyclosporine 0.05% (6,800), autologous serum 50% (313), vancomycin 5% (200) and ceftazidime 5% (150). The main increase was concentrated in autologous serum 20% eye drops and cyclosporine 0.05% eye drops (17% and 20%, respectively).

The preparation of intraocular injections were 3592 (2017) and 3128 (2016). During 2017, the five preparations with the highest number of preparations were: cefuroxime 1 mg/0.1 ml (1,630); aflibercept 2 mg/0.05 ml (1,193); vancomycin 1 mg/0.1 ml (481); ceftazidime 2 mg/0.1 ml (130); and bevacizumab 5 mg/0.2 ml (74). It can be observed that these five preparations were 96% of the total intraocular injections. The main increase was concentrated in the saving of aflibercept 2 mg/0.05 ml intraocular injections.

It has also been shown that bevacizumab 2.5% eye drops (€12,008,4/year) and intravitreal syringes of aflibercept 2 mg/0.05 ml (€244,920/year) account for 98% of the total expense (€260,920) in ophthalmology preparations.

Conclusion The ophthalmological preparations in a pharmacy hospital have increased by 19%. Autologous serum 20% and cyclosporine 0.05% were impacted of 92% eye drops, including the longest storage duration tested. They must be prepared in the pharmacy service according to quality criteria to ensure its effectiveness, stability and sterility,1 and supposed a high economic impact (€260,816.76)

Reference and/or acknowledgements

  1. Fuentes-Irigoyen R, Martin de Rosales Cabrera AM, Riestra AC, et al. Consenso SEO-SEFH sobre recomendaciones de utilizacion y elaboracion de preparaciones oftalmicas. Farm Hosp 2018;42:82–8.

Reference and/or acknowledgementsNo conflict of interest.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.